Back to Search Start Over

123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression

Authors :
A. Rittmeyer
E. Felip
N.K. Altorki
E. Vallieres
C. Zhou
A. Martinez-Marti
T. Csoszi
M. Reck
M.E. Teixeira
Y. Deng
M. Huang
V.A. McNally
E. Bennett
B.J. Gitlitz
M. Srivastava
H. Wakelee
Source :
Immuno-Oncology and Technology. 16:100235
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Subjects

Subjects :
Oncology
Immunology and Allergy

Details

ISSN :
25900188
Volume :
16
Database :
OpenAIRE
Journal :
Immuno-Oncology and Technology
Accession number :
edsair.doi...........3fa3c0ff73f3b52fd306b7ee51bfbc85
Full Text :
https://doi.org/10.1016/j.iotech.2022.100235
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details